Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases affecting bone health and blood vessel function, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference.
The company's CEO and Chairman, Doug Treco, Ph.D., will deliver a presentation on Monday, March 3, 2025, from 1:10-1:40pm ET. Interested parties can access a live webcast of the presentation through the Investor Relations section of Inozyme's website under the events tab. A replay will be available for a time following the presentation.
Inozyme Pharma (Nasdaq: INZY), una società biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per malattie rare che colpiscono la salute delle ossa e la funzione dei vasi sanguigni, ha annunciato la sua prossima partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen.
Il CEO e Presidente dell'azienda, Doug Treco, Ph.D., terrà una presentazione lunedì 3 marzo 2025, dalle 13:10 alle 13:40 ET. Le parti interessate possono accedere a una trasmissione in diretta della presentazione attraverso la sezione Relazioni con gli Investitori del sito web di Inozyme, nella scheda eventi. Una registrazione sarà disponibile per un periodo di tempo dopo la presentazione.
Inozyme Pharma (Nasdaq: INZY), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias para enfermedades raras que afectan la salud ósea y la función de los vasos sanguíneos, ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud de TD Cowen.
El CEO y Presidente de la empresa, Doug Treco, Ph.D., realizará una presentación el lunes 3 de marzo de 2025, de 1:10 a 1:40 p.m. ET. Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de Relaciones con Inversores del sitio web de Inozyme, en la pestaña de eventos. Una repetición estará disponible por un tiempo después de la presentación.
Inozyme Pharma (Nasdaq: INZY)는 뼈 건강과 혈관 기능에 영향을 미치는 희귀 질환 치료제를 개발하는 임상 단계의 생명공학 회사로, TD Cowen 제45회 연례 건강 관리 컨퍼런스에 참여할 예정이라고 발표했습니다.
회사의 CEO이자 회장인 Doug Treco, Ph.D.는 2025년 3월 3일 월요일, 오후 1시 10분부터 1시 40분까지 ET에 발표를 진행합니다. 관심 있는 분들은 Inozyme 웹사이트의 투자자 관계 섹션 이벤트 탭을 통해 발표의 실시간 웹캐스트에 접속할 수 있습니다. 발표 후 일정 기간 동안 재생이 가능합니다.
Inozyme Pharma (Nasdaq: INZY), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies pour des maladies rares affectant la santé osseuse et la fonction des vaisseaux sanguins, a annoncé sa prochaine participation à la 45ème Conférence Annuelle sur la Santé de TD Cowen.
Le PDG et Président de l'entreprise, Doug Treco, Ph.D., fera une présentation le lundi 3 mars 2025, de 13h10 à 13h40 ET. Les parties intéressées peuvent accéder à une diffusion en direct de la présentation via la section Relations Investisseurs du site Web d'Inozyme sous l'onglet événements. Un enregistrement sera disponible pendant un certain temps après la présentation.
Inozyme Pharma (Nasdaq: INZY), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapeutika für seltene Krankheiten konzentriert, die die Knochengesundheit und die Funktion der Blutgefäße beeinträchtigen, hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben.
Der CEO und Vorsitzende des Unternehmens, Doug Treco, Ph.D., wird am Montag, dem 3. März 2025, von 13:10 bis 13:40 Uhr ET eine Präsentation halten. Interessierte Parteien können über den Bereich Investor Relations der Website von Inozyme unter dem Tab Veranstaltungen auf einen Live-Stream der Präsentation zugreifen. Eine Aufzeichnung wird für eine gewisse Zeit nach der Präsentation verfügbar sein.
- None.
- None.
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, from 1:10-1:40pm ET.
A live webcast of the presentation can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the event will also be available for a limited time.
About Inozyme Pharma
Inozyme Pharma is a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. We are experts in the PPi-Adenosine Pathway, where the ENPP1 enzyme generates inorganic pyrophosphate (PPi), which regulates mineralization, and adenosine, which controls intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels). Disruptions in this pathway impact the levels of these molecules, leading to severe musculoskeletal, cardiovascular, and neurological conditions, including ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL).
Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these molecules. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases.
For more information, please visit www.inozyme.com and follow us on LinkedIn, X, and Facebook.
Contacts
Investors:
Inozyme Pharma
Stefan Riley, Director of IR and Corporate Communications
(857) 330-8871
stefan.riley@inozyme.com
Media:
Biongage Communications
Todd Cooper
(617) 840-1637
todd@biongage.com
FAQ
When is Inozyme Pharma (INZY) presenting at the TD Cowen Health Care Conference 2025?
How can investors watch Inozyme Pharma's (INZY) TD Cowen conference presentation?
What type of diseases does Inozyme Pharma (INZY) focus on treating?
Who will represent Inozyme Pharma (INZY) at the TD Cowen Healthcare Conference 2025?
